UNSPSC 51432313: Losartan potassium

This classification denotes an angiotensin ii receptor antagonist with the molecular formula C22H22ClN6O.K, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3ST302B24A, chemically known as 2-butyl-4-chloro-1-(p-(o-1h-tetrazol-5-ylphenyl)benzyl)imidazole-5-methanol, monopotassium salt but more generally known as losartan potassium, which bears US NIH Compound Identifier 60771. European Medicines Agency schedules Losartan potassium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02974MIG.

UNSPSC 51432313 Losartan potassium is a Commodity code covering specific pharmaceutical products supplied to state and local government healthcare and emergency medical service operations. State and local governments procure this medication and related pharmaceuticals through direct purchase orders, cooperative purchasing agreements, and emergency medical services supply contracts. Issuing bodies include city fire and rescue departments, state health and human services agencies, and regional purchasing consortiums that aggregate demand across multiple jurisdictions. The scope of procurement extends beyond losartan alone to broader advanced life support and multi-source generic pharmaceutical programs that bundle individual drug line items for efficiency and cost control.

Recent activity shows geographic concentration in Florida and Texas, with cooperative purchasing extending to Minnesota and Oregon. The City of Tampa's Purchasing Department issued Bid 26P00188 in April 2026 for Advanced Life Support Medications to supply Tampa Fire Rescue, an IFB seeking four specific medication line items with a nine-month minimum expiration requirement and delivery within ten calendar days, estimated at $40,000 with a one-year contract term and renewal options, closing April 8, 2026. The Texas Health and Human Services Commission issued RFI HHS0017013 in April 2026 to explore direct-to-manufacturer prescription fulfillment capability and contracting models for future state pharmacy programs. The Minnesota Department of Administration's Office of State Procurement administered an RFP through MMCAP in January 2026 for generic multi-source pharmaceuticals and OTC products across state and local facilities in Minnesota and Oregon, requiring vendors to supply through three authorized wholesalers with products available by May 15, 2026 and effective July 1, 2026, due March 26, 2026, weighted heavily on price competitiveness at 75 percent and subject to a 3 percent administrative fee.